Sana Biotechnology (NASDAQ:SANA) Trading Down 4.8%

Sana Biotechnology, Inc. (NASDAQ:SANA)’s stock price was down 4.8% on Friday . The company traded as low as $5.13 and last traded at $5.15. Approximately 135,053 shares changed hands during trading, a decline of 94% from the average daily volume of 2,345,430 shares. The stock had previously closed at $5.41.

Analysts Set New Price Targets

A number of analysts recently weighed in on SANA shares. Citigroup raised their target price on shares of Sana Biotechnology from $8.00 to $15.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Rodman & Renshaw started coverage on shares of Sana Biotechnology in a report on Wednesday, June 26th. They set a “buy” rating and a $16.00 target price for the company. Finally, HC Wainwright reduced their target price on shares of Sana Biotechnology from $12.00 to $11.00 and set a “buy” rating for the company in a report on Friday, August 9th.

Sana Biotechnology Trading Down 8.1 %

The firm has a market cap of $1.11 billion, a PE ratio of -3.33 and a beta of 1.45. The company’s 50-day moving average is $5.55 and its 200 day moving average is $7.41.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.04). On average, research analysts predict that Sana Biotechnology, Inc. will post -1.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Sana Biotechnology

Several hedge funds have recently made changes to their positions in the company. Algert Global LLC purchased a new stake in shares of Sana Biotechnology in the 2nd quarter valued at approximately $73,000. The Manufacturers Life Insurance Company lifted its position in Sana Biotechnology by 8.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 312,031 shares of the company’s stock worth $1,704,000 after buying an additional 23,157 shares in the last quarter. Dark Forest Capital Management LP lifted its position in Sana Biotechnology by 112.0% in the 2nd quarter. Dark Forest Capital Management LP now owns 27,314 shares of the company’s stock worth $149,000 after buying an additional 14,430 shares in the last quarter. Squarepoint Ops LLC lifted its position in Sana Biotechnology by 318.8% in the 2nd quarter. Squarepoint Ops LLC now owns 126,572 shares of the company’s stock worth $691,000 after buying an additional 96,348 shares in the last quarter. Finally, Integral Health Asset Management LLC lifted its position in Sana Biotechnology by 22.4% in the 2nd quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company’s stock worth $6,552,000 after buying an additional 220,000 shares in the last quarter. Hedge funds and other institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.